Solvonis Therapeutics plc Announces US Patent Office Allows Ketamine Patent Across All Behavioural Addictions
London, United Kingdom--(Newsfile Corp. - November 5, 2026) - Solvonis Therapeutics plc (LSE: SVNS), a clinical-stage biotechnology company developing psychedelic therapeutics for addiction, post-traumatic stress disorder ("PTSD") and depression, announces that the US Patent an
2026-11-05 9:21 AM EST